SUPERNUS PHARMACEUTICALS INC (SUPN)
Health Care · Specialty Pharmaceuticals · NASDAQ
A CNS-focused biopharmaceutical company developing and commercializing treatments for epilepsy, ADHD, and other neurological disorders.
What SUPERNUS PHARMACEUTICALS INC does
Supernus Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system (CNS) diseases. Its portfolio includes therapies for epilepsy, ADHD, and other neurological and psychiatric disorders. The company also generates revenue through collaboration agreements, notably including ZURZUVAE.
Themes: CNS disorders / neurology, epilepsy / seizure disorders, ADHD / mental health, collaboration revenue
Fundamentals
- Price$45.85 as of 2026-08-21 close
- Market cap$2.7B as of 2026-08-21
- 1-year return+5.8% 2025-08-21 close $43.32 → 2026-08-21 close $45.85
- P/En/a negative earnings
- Net margin-13.2% as of 2026-08-24
- Gross margin+88.3% as of 2026-08-24
- ROE-10.4% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+24.9% as of 2026-08-24
- Revenue CAGR (3y)+2.5% SEC XBRL
- Beta0.57 as of 2026-08-24
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How SUPN compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
SUPN is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
45.5 #1099 of 1,704 scored · #187 of 240 in Health Care
Setup 55th: no fresh 20-day breakout up or down; volume and participation 55th: trading volume is about normal versus its 30-day average; weakest is catalysts 37th: analysts have cut their average price target by 1.2% since the prior reading.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How SUPERNUS PHARMACEUTICALS INC looks technically
SUPERNUS PHARMACEUTICALS INC (SUPN) is trading 5.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 50 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 4 trading days ago. It is 23.2% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 5.9% below its 200-day average, the long-term trend line — a long-term downtrend | -5.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $46.69 | $46.69 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $48.73 | $48.73 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 50 trading days ago — a "death cross", a bearish long-term signal | 50 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control | 26.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30) | 44.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($42.63 to $49.81) — its "stochastic" reading is 45 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 44.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $59.68 | $59.68 |
|---|---|---|
| From the 52-week high | it is 23.2% below its 52-week high (its highest price of the past year) | -23.2% |
| Above the 52-week low | it is 9.7% above its 52-week low (its lowest price of the past year) | +9.7% |
| Below the 52-week high | it is 23.2% below its highest point of the past year | 23.2% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day low about 14 trading days ago | 14 sessions |
| All-time high | its highest closing price on record is $61.25 (set on 2018-06-29) | $61.25 |
| Given back of the 52-week move | over the past year its closes ranged ($42.00 to $57.00), and it has given back well over two thirds of its rise from last year’s low — 74% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $47.25 to $47.73. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 74.3% |
| From the all-time high | it is 25.1% below its all-time high | -25.1% |
| Nearest price level | it is sitting right on a resistance level at $45.99 — a price it turned at twice since 2026-06-11, most recently on 2026-07-14. Since 2024-08-21 it has 8 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.3% |
| All-time low | its lowest closing price on record is $4.30 (set on 2012-06-05) | $4.30 |
| Above the all-time low | it is 966.3% above its all-time low | +966.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 51st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.87 between its high and its low — about 4.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.87 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $44.25 and $49.60 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $44.25 – $46.92 – $49.60 |
| Typical daily range (% of price) | its price moves about 4.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.1% |
| Stretch from the 200-day average | it is trading 1.5 daily ranges below its 200-day average price (5.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.87× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.2% since the prior reading | -1.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.6% |
|---|---|---|
| Gap filled | a 13.0% gap up opened on 2026-08-03 has been "filled" 14 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 14 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -6.49% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 6.6 percentage points (the stock lost 4.2% while the market gained 2.3%) | -6.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 10.2 percentage points (the stock lost 7.1% while the market gained 3.1%) | -10.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 20.9 percentage points (the stock lost 9.9% while the market gained 11.1%) | -20.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 14.6 percentage points (the stock gained 5.8% while the market gained 20.5%) | -14.6% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.9% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.3% of the share price, which is taken to mean a barrier that gives way easily. | -3.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $48.91 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -6.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-07-22 (its 8-K), so the typical buyer over that stretch is under water. That average is $46.32 — a volume-weighted average of daily closes over 23 sessions, not a true tick-by-tick VWAP. | -1.0% |
Price levels it has turned at before
SUPN last closed at $45.85 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $45.99 | Resistance | 0.3% above the last close | turned there twice · 2026-06-11 to 2026-07-14 |
| $47.01 | Resistance | 2.5% above the last close | turned there six times · 2025-09-08 to 2026-05-06 |
| $43.73 | Support | 4.6% below the last close | turned there five times · 2025-08-06 to 2026-06-03 |
| $48.03 | Resistance | 4.8% above the last close | turned there three times · 2026-01-06 to 2026-04-16 |
| $42.73 | Support | 6.8% below the last close | turned there three times · 2025-11-05 to 2026-08-04 |
| $40.13 | Support | 12.5% below the last close | turned there twice · 2025-02-05 to 2025-02-18 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · in a strong, established uptrend (ADX) · Analyst price target recently CUT · lagging the market · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$61.75 range $55.00 – $67.00; median $62.50
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SUPN
- Consensus EPS estimate$0.615 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant reliance on a limited number of commercial products.","Exposure to risks related to intangible asset impairment charges.","Potential for product return liabilities and pharmaceutical pricing/rebate pressures."]
What changed in the latest 10-Q
AI-assisted comparison of SUPN's 10-Q filed 2026-05-05 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-05) references audited consolidated financial statements for year ended December 31, 2025 filed March 2, 2026
- Newer filing (2026-05-05) includes section titled '2025 Acquisition of Sage Therapeutics, Inc. (Sage) and Reorganization' describing July 31, 2025 completion of Sage acquisition and Q3 2025 reorganization into LLC
- Removed:
- Older filing (2025-11-06) referenced audited consolidated financial statements for year ended December 31, 2024 filed February 25, 2025
- Older filing (2025-11-06) contained detailed '2025 Acquisition of Sage Therapeutics, Inc.' section with acquisition and reorganization details
- Reworded:
- Overview section: Older filing (2025-11-06) stated 'new potential treatments for epilepsy, depression, attention deficit hyperactivity disorder (ADHD) and other CNS disorders' while newer filing (2026-05-05) states 'new potential treatments for epilepsy, depression, and other CNS disorders' (removed redundant ADHD reference)
- Notes:
- The older filing text provided is truncated at the Commercial Products section and does not show complete content; comparison limited to available text
- The newer filing text is also truncated mid-sentence in the Research and Development section; full section comparison not possible
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 15 sells ($9M) — 6 selling insiders
Most recent open-market transaction: 2026-03-18. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SUPN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for SUPN from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding SUPN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 14,528,019
- Reported value $750,953,321
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SUPN had 4,816,923 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SUPN had 8.29% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.51 days to cover at the same settlement.
- Reported short interest (shares) 4,816,923
- Short interest (% of shares outstanding) 8.29%
- Prior settlement (shares) 4,850,861
- Reported change -0.7%
- Days to cover (reported) 9.51
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- UCB (UCBJF)
- Jazz Pharmaceuticals (JAZZ)
- Lundbeck (HLUYY)
- Acadia Pharmaceuticals (ACAD)
- Teva Pharmaceutical Industries (TEVA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SUPN vs…
Frequently asked questions
What does SUPERNUS PHARMACEUTICALS INC (SUPN) do?
Supernus Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system (CNS) diseases. Its portfolio includes therapies for epilepsy, ADHD, and other neurological and psychiatric disorders. The company also generates revenue through collaboration agreements, notably including ZURZUVAE.
What sector is SUPERNUS PHARMACEUTICALS INC (SUPN) in?
SUPERNUS PHARMACEUTICALS INC (SUPN) is classified in the Health Care sector. Its industry is Specialty Pharmaceuticals. It trades on NASDAQ.
Who are SUPERNUS PHARMACEUTICALS INC's (SUPN) competitors?
Notable peers of SUPERNUS PHARMACEUTICALS INC (SUPN) include UCB, Jazz Pharmaceuticals, Lundbeck, Acadia Pharmaceuticals and Teva Pharmaceutical Industries. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in SUPN?
Yes — we hold 4 matched STOCK Act disclosures for SUPN from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is SUPERNUS PHARMACEUTICALS INC (SUPN) overbought or oversold right now?
SUPERNUS PHARMACEUTICALS INC (SUPN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 45, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SUPN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.